56453366

CONFIDENTIAL

Integrated BRACAnalysis® with MyRisk™ Hereditary Cancer Test

MyRisk Genetic Result

MyRisk™ Hereditary Cancer Test

RECEIVING HEALTHCARE PROVIDER

Amy Kowalski, CNS
Inspire Family Health
711 W 38TH ST STE F3
AUSTIN, TX 78705

SPECIMEN

Specimen Type:	Blood
Draw Date:	May 08, 2025
Accession Date:	May 10, 2025
Report Date:	May 22, 2025

PATIENT

Legal Name:	Ladnier, William
Date of Birth:	Oct 24, 1990
Patient ID:	
Sex at Birth:	M
Accession #:	05401802-BLD
Requisition #:	11892680

GENETIC RESULT: NEGATIVE - NO CLINICALLY SIGNIFICANT MUTATION IDENTIFIED

At this time, any genetic changes identified in this report are not known to warrant modification of the patient's medical management beyond what is indicated by the patient's personal and family history.

CLINICAL HISTORY ANALYSIS: NO ADDITIONAL MANAGEMENT GUIDELINES IDENTIFIED BASED ON THE CLINICAL HISTORY PROVIDED

Other clinical factors may influence individualized management. This analysis may be incomplete if details about cancer diagnoses, ages, family relationships or other factors were omitted or ambiguous. If this patient also has a clinically significant mutation, the recommendations based on the clinical history analysis should be considered in light of the possibility that this mutation explains all or some of the cancer history in the family.

ADDITIONAL FINDINGS: NO VARIANT(S) OF UNCERTAIN SIGNIFICANCE (VUS) IDENTIFIED

Details About Non-Clinically Significant Variants: All individuals carry DNA changes (i.e., variants), and most variants do not increase an individual's risk of cancer or other diseases. When identified, variants of uncertain significance (VUS) are reported. Likely benign variants (Favor Polymorphisms) and benign variants (Polymorphisms) are not reported and available data indicate that these variants most likely do not cause increased cancer risk. Present evidence does not suggest that non-clinically significant variant findings be used to modify patient medical management beyond what is indicated by the personal and family history and any other clinically significant findings.

Variant Classification: Myriad's myVision™ Variant Classification Program performs ongoing evaluations of variant classifications. In certain cases, healthcare providers may be contacted for more clinical information or to arrange family testing to aid in variant classification. When new evidence about a variant is identified and determined to result in clinical significance and management change, that information will automatically be made available to the healthcare provider through an amended report.

ADDITIONAL INFORMATION

Genes Analyzed: Sequencing (seq) and large rearrangement analyses were performed for all coding exons in the following genes, unless otherwise indicated:
APC, *ATM*, *AXIN2*, *BAP1*, *BARD1*, *BMPR1A*, *BRCA1*, *BRCA2*, *BRIP1*, *CDH1*, *CDK4*, *CDKN2A*, *CHEK2*, *CTNNA1*, *FH*, *FLCN*, *HOXB13* (seq only), *MEN1*, *MET*, *MLH1*, *MSH2*, *MSH3* (excluding repetitive portions of exon 1), *MSH6*, *MUTYH*, *NTHL1*, *PALB2*, *PMS2*, *PTEN*, *RAD51C*, *RAD51D*, *SDHA*, *SDHB*, *SDHC*, *SDHD*, *SMAD4*, *STK11*, *TP53*, *TSC1*, *TSC2*, *VHL*.
Limited promoter regions may also be analyzed for large rearrangements.

Sequencing (seq) and/or large rearrangement (LR) analyses were performed only for the gene portions indicated in parenthesis for the following genes:
EGFR (exons 18-21, seq and LR), *EPCAM* (exons 8-9, LR only), *GREM1* (exon 1 and upstream regulatory regions, LR only), *MITF* (c.952, seq only), *POLE* (exonuclease domain, seq only), *POLD1* (exonuclease domain, seq only), *RET* (exons 5, 8, 10, 11, 13-16 seq and LR), *TERT* (promoter region 71 bases upstream of the translation start, c.-71_-1, seq only).

** Other genes not analyzed with this test may also be associated with cancer.

Myriad genetics

MyRisk Genetic Result

Name: **Ladnier, William** DOB: **Oct 24, 1990** Accession #: **05401802-BLD** Report Date: **May 22, 2025**

Indication for Testing: It is our understanding that this individual was identified for testing due to a personal or family history suggestive of a hereditary predisposition for cancer.

Patient Information: Sex assigned at birth is a label given to an individual at birth, typically "male" or "female". In this report, the terms "male", "female", "he", "she", "woman", and "man" refer to sex assigned at birth.

Associated Cancer Risks and Clinical Management: The "MyRisk Management Tool" associated with this report provides a summary of cancer risk and professional society medical management guidelines that may be useful in developing a plan for this patient based on any clinically significant test results and/or reported personal/family history. In some cases, a MyRisk Management Tool cannot be provided, such as when the result has a special interpretation or includes a mutation with unusual characteristics.

Analysis Description: The Technical Specifications summary (myriad.com/technical-specifications) describes the analysis, method, performance, nomenclature, and interpretive criteria of this test. Current testing technologies are unable to definitively determine whether a variant is germline or somatic in origin, which may significantly impact risk estimates and medical management; therefore, these results should be correlated with this patient's personal and family history. The interpretation of this test may also be impacted if the patient has a hematologic malignancy or an allogeneic bone marrow transplant.

CLASSIFICATION DISCLAIMER

THE CLASSIFICATION AND INTERPRETATION OF ALL VARIANTS IDENTIFIED IN THIS ASSAY REFLECTS THE CURRENT STATE OF MYRIAD'S SCIENTIFIC UNDERSTANDING AT THE TIME THIS REPORT WAS ISSUED. VARIANT CLASSIFICATION AND INTERPRETATION MAY CHANGE FOR A VARIETY OF REASONS, INCLUDING BUT NOT LIMITED TO, IMPROVEMENTS TO CLASSIFICATION TECHNIQUES, AVAILABILITY OF ADDITIONAL SCIENTIFIC INFORMATION, AND OBSERVATION OF A VARIANT IN MORE PATIENTS.

Please contact Myriad Medical Services at 1-800-469-7423 X 3850 to discuss any questions regarding this result.

These test results should only be used in conjunction with the patient's clinical history and any previous analysis of appropriate family members. The patient's clinical history and test results should not be disclosed to a third party, unless related to treatment or payment for treatment, without the patient's express written authorization. It is strongly recommended that these results be communicated to the patient in a setting that includes appropriate genetic consultation. This test was developed and its performance characteristics determined by Myriad Genetic Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that clearance or approval for laboratory-developed tests is not required.

This **Authorized Signature** pertains to this laboratory report:



Benjamin B. Roa, PhD
Diplomate ABMGG
Laboratory Director

Genetic testing was completed by CLIA and CAP accredited laboratories in the United States located at: 320 Wakara Way, Salt Lake City, UT 84108 and 322 N 2200 W, Salt Lake City, UT 84116 CLIA IDs: 46D0880690, 46D2275645
The following personnel codes and laboratory director signature may reflect remote review of digital data: 28492, 29041

Myriad genetics

Integrated BRACAnalysis® with MyRisk™ Hereditary Cancer Test

Clinical & Cancer Family History Information

MyRisk™ Hereditary Cancer Test

RECEIVING HEALTHCARE PROVIDER

Amy Kowalski, CNS
Inspire Family Health
711 W 38TH ST STE F3
AUSTIN, TX 78705

SPECIMEN

Specimen Type: Blood
Draw Date: May 08, 2025
Accession Date: May 10, 2025
Report Date: May 22, 2025

PATIENT

Legal Name: Ladnier, William
Date of Birth: Oct 24, 1990
Patient ID:
Sex at Birth: M
Accession #: 05401802-BLD
Requisition #: 11892680

PERSONAL / FAMILY CANCER HISTORY SUMMARY

FAMILY MEMBER	CANCER / CLINICAL DIAGNOSIS	AGE AT DIAGNOSIS
Patient	None	
Grandfather Maternal	Prostate	64
Uncle Maternal	Prostate	66
Great Grandfather Maternal	Prostate	72

The clinical information displayed here was provided by a qualified healthcare provider on the Test Request Form and other documents, and was not verified by Myriad. Female relatives refers to sex assigned at birth, which is a label given to an individual at birth, typically "male" or "female". Family members listed as "other" are not included in a Tyrer-Cuzick breast cancer risk estimate or other personal/family history assessments. For more information see the Specifications for Personal/Family History Analysis at http://myriad.com/technical-specifications.

The accuracy and completeness of the information provided in the Clinical and Cancer Family History Information section of the report (e.g. height and weight, age of menarche) may significantly affect the accuracy of breast cancer risk estimates provided based on either Tyrer-Cuzick or RiskScore. The impact of breast surgeries and hormone therapy (except hormone replacement therapy) have not been assessed or validated for Tyrer-Cuzick and RiskScore.

RiskScore is not valid, and may significantly over- or under-estimate breast cancer risk for individuals who do not meet the eligibility criteria in effect when the testing was performed. The current criteria are: 1) sex assigned at birth is female 2) age is 18 to 84 years, 3) no personal history of breast cancer, LCIS, hyperplasia (with or without atypia), or a breast biopsy with unknown results, 4) there is no mutation detected in a breast cancer risk gene (other than a monoallelic *CHEK2* mutation in a White/Non-Hispanic or Ashkenazi Jewish individual), 5) the individual's relatives have not been found to have a mutation in a high-penetrance breast cancer risk gene (*BRCA1*, *BRCA2*, *CDH1*, *PALB2*, *PTEN*, *STK11*, *TP53*, a biallelic mutation in *CHEK2*, or the specific mutation c.7271T>G (p.Val2424Gly) in *ATM*) and 6) the sample was submitted with a current Test Request Form and the ordering healthcare provider has not determined that RiskScore is inappropriate for the patient. If this is an amended report for a patient tested in the past, please refer to the MyRisk Technical Specifications at http://myriad.com/technical-specifications for the eligibility criteria in effect at the time of the original testing.

Integrated BRACAnalysis® with MyRisk™ Hereditary Cancer Test

MyRisk Management Tool

MyRisk™ Hereditary Cancer Test

RECEIVING HEALTHCARE PROVIDER

Amy Kowalski, CNS
Inspire Family Health
711 W 38TH ST STE F3
AUSTIN, TX 78705

SPECIMEN

Specimen Type:	Blood
Draw Date:	May 08, 2025
Accession Date:	May 10, 2025
Report Date:	May 22, 2025

PATIENT

Legal Name:	Ladnier, William
Date of Birth:	Oct 24, 1990
Patient ID:	
Sex at Birth:	M
Accession #:	05401802-BLD
Requisition #:	11892680

GENETIC RESULT: NEGATIVE - NO CLINICALLY SIGNIFICANT MUTATION IDENTIFIED

At this time, any genetic changes identified in this report are not known to warrant modification of the patient's medical management beyond what is indicated by the patient's personal and family history.

CLINICAL HISTORY ANALYSIS: NO ADDITIONAL MANAGEMENT GUIDELINES IDENTIFIED BASED ON THE CLINICAL HISTORY PROVIDED

Other clinical factors may influence individualized management. This analysis may be incomplete if details about cancer diagnoses, ages, family relationships or other factors were omitted or ambiguous. If this patient also has a clinically significant mutation, the recommendations based on the clinical history analysis should be considered in light of the possibility that this mutation explains all or some of the cancer history in the family.

No clinically significant mutations were identified in this patient. However, based on personal/family history, the patient's cancer risks may still be increased over the general population. See information below.

Please see the Genetic Test Result for more details on any variant(s) detected in this patient, including variant classification information.

The terms "male", "female", "he", "she", "women", and "men" refer to sex assigned at birth.

ADDITIONAL FINDINGS: NO VARIANT(S) OF UNCERTAIN SIGNIFICANCE (VUS) IDENTIFIED

Notes for Personalized Management:

INFORMATION ON HOW CANCER RISKS AND MANAGEMENT ARE DETERMINED

The MyRisk Management Tool provides cancer risk levels based on analysis of genetic test results (see MyRisk Genetic Result) and a summary of medical society management recommendations based on both the genetic test results and a limited analysis of the patient's clinical history related to the risk for breast, colorectal, prostate, melanoma and pancreatic cancers. Here are some important points to understand as you interpret this test report and decide on the best plan for management:

- Comprehensive patient management. The management recommendations presented in this report are a summary of management options recommended by the National Comprehensive Cancer Network (NCCN) and other established medical societies and are general in nature. The patient's actual management should be modified based on personal medical history, surgeries and other treatments. A comprehensive risk assessment and management plan may take into account this report and other aspects of the patient's personal/family medical history (e.g., all known clinical diagnoses), as well as lifestyle, environmental and other factors.

Myriad genetics

- Risk estimates based on provider-supplied information. Some of the risk estimates and management recommendation summaries provided in this report are based on our interpretation of information supplied by the ordering health care provider on the test request form (see Specifications for Personal/Family History analysis at myriad.com/technical-specifications). The patient's actual risks and appropriate management may be significantly different if details provided for cancer diagnoses, ages, family relationships or other factors were incorrect, omitted, ambiguous or have since changed. Please review the clinical history listed on the Clinical & Family History Information page of this report to make sure that the information used was provided and interpreted correctly.
- Variability in Tyrer-Cuzick risk estimates. Tyrer-Cuzick estimates of breast cancer risk can vary significantly based on the way in which the model is used, and the estimate provided here may be higher or lower than what would be calculated by other users. For complete details of how Myriad calculates Tyrer-Cuzick risk estimates, including how Myriad handles information provided in a format not compatible with the model, please see the Specifications for Personal/Family History analysis at myriad.com/technical-specifications. These Specifications also include information for recalculating the Tyrer-Cuzick breast cancer risk estimate if desired.
- What is meant by "High Risk" and "Elevated Risk"? In the Genetic Test Result Summary, a gene-associated cancer risk is described as "High Risk" for a cancer type if all of the following conditions are met: the absolute risk of cancer is approximately 5% or higher, the increase in risk over the general population is approximately 2 to 3-fold or higher, and there is significant data from multiple studies supporting the cancer risk estimate. A gene is described as "Elevated Risk" for a cancer type if there is sufficient data to support an increase in cancer risk over the general population risk, but not all criteria for "High Risk" are met.

INFORMATION FOR FAMILY MEMBERS

Family members should talk to their healthcare providers about hereditary cancer testing to help define their own risk and assist in the interpretation of this patient's genetic test result.

Please contact Myriad Medical Services at 1-800-469-7423 X 3850 to discuss any questions regarding this result.

END OF MANAGEMENT TOOL

56453366

PATIENT COPY CONFIDENTIAL

Integrated BRACAnalysis® with MyRisk™ Hereditary Cancer Test

MyRisk Genetic Result

MyRisk™ Hereditary Cancer Test

RECEIVING HEALTHCARE PROVIDER

Amy Kowalski, CNS
Inspire Family Health
711 W 38TH ST STE F3
AUSTIN, TX 78705

SPECIMEN

Specimen Type:	Blood
Draw Date:	May 08, 2025
Accession Date:	May 10, 2025
Report Date:	May 22, 2025

PATIENT

Legal Name:	Ladnier, William
Date of Birth:	Oct 24, 1990
Patient ID:	
Sex at Birth:	M
Accession #:	05401802-BLD
Requisition #:	11892680

GENETIC RESULT: NEGATIVE - NO CLINICALLY SIGNIFICANT MUTATION IDENTIFIED

At this time, any genetic changes identified in this report are not known to warrant modification of the patient's medical management beyond what is indicated by the patient's personal and family history.

CLINICAL HISTORY ANALYSIS: NO ADDITIONAL MANAGEMENT GUIDELINES IDENTIFIED BASED ON THE CLINICAL HISTORY PROVIDED

Other clinical factors may influence individualized management. This analysis may be incomplete if details about cancer diagnoses, ages, family relationships or other factors were omitted or ambiguous. If this patient also has a clinically significant mutation, the recommendations based on the clinical history analysis should be considered in light of the possibility that this mutation explains all or some of the cancer history in the family.

ADDITIONAL FINDINGS: NO VARIANT(S) OF UNCERTAIN SIGNIFICANCE (VUS) IDENTIFIED

Details About Non-Clinically Significant Variants: All individuals carry DNA changes (i.e., variants), and most variants do not increase an individual's risk of cancer or other diseases. When identified, variants of uncertain significance (VUS) are reported. Likely benign variants (Favor Polymorphisms) and benign variants (Polymorphisms) are not reported and available data indicate that these variants most likely do not cause increased cancer risk. Present evidence does not suggest that non-clinically significant variant findings be used to modify patient medical management beyond what is indicated by the personal and family history and any other clinically significant findings.

Variant Classification: Myriad's myVision™ Variant Classification Program performs ongoing evaluations of variant classifications. In certain cases, healthcare providers may be contacted for more clinical information or to arrange family testing to aid in variant classification. When new evidence about a variant is identified and determined to result in clinical significance and management change, that information will automatically be made available to the healthcare provider through an amended report.

ADDITIONAL INFORMATION

Genes Analyzed: Sequencing (seq) and large rearrangement analyses were performed for all coding exons in the following genes, unless otherwise indicated:
APC, *ATM*, *AXIN2*, *BAP1*, *BARD1*, *BMPR1A*, *BRCA1*, *BRCA2*, *BRIP1*, *CDH1*, *CDK4*, *CDKN2A*, *CHEK2*, *CTNNA1*, *FH*, *FLCN*, *HOXB13* (seq only), *MEN1*, *MET*, *MLH1*, *MSH2*, *MSH3* (excluding repetitive portions of exon 1), *MSH6*, *MUTYH*, *NTHL1*, *PALB2*, *PMS2*, *PTEN*, *RAD51C*, *RAD51D*, *SDHA*, *SDHB*, *SDHC*, *SDHD*, *SMAD4*, *STK11*, *TP53*, *TSC1*, *TSC2*, *VHL*.
Limited promoter regions may also be analyzed for large rearrangements.

Sequencing (seq) and/or large rearrangement (LR) analyses were performed only for the gene portions indicated in parenthesis for the following genes:
EGFR (exons 18-21, seq and LR), *EPCAM* (exons 8-9, LR only), *GREM1* (exon 1 and upstream regulatory regions, LR only), *MITF* (c.952, seq only), *POLE* (exonuclease domain, seq only), *POLD1* (exonuclease domain, seq only), *RET* (exons 5, 8, 10, 11, 13-16 seq and LR), *TERT* (promoter region 71 bases upstream of the translation start, c.-71_-1, seq only).

** Other genes not analyzed with this test may also be associated with cancer.

Myriad genetics

MyRisk Genetic Result

Name: **Ladnier, William** DOB: **Oct 24, 1990** Accession #: **05401802-BLD** Report Date: **May 22, 2025**

Indication for Testing: It is our understanding that this individual was identified for testing due to a personal or family history suggestive of a hereditary predisposition for cancer.

Patient Information: Sex assigned at birth is a label given to an individual at birth, typically "male" or "female". In this report, the terms "male", "female", "he", "she", "woman", and "man" refer to sex assigned at birth.

Associated Cancer Risks and Clinical Management: The "MyRisk Management Tool" associated with this report provides a summary of cancer risk and professional society medical management guidelines that may be useful in developing a plan for this patient based on any clinically significant test results and/or reported personal/family history. In some cases, a MyRisk Management Tool cannot be provided, such as when the result has a special interpretation or includes a mutation with unusual characteristics.

Analysis Description: The Technical Specifications summary (myriad.com/technical-specifications) describes the analysis, method, performance, nomenclature, and interpretive criteria of this test. Current testing technologies are unable to definitively determine whether a variant is germline or somatic in origin, which may significantly impact risk estimates and medical management; therefore, these results should be correlated with this patient's personal and family history. The interpretation of this test may also be impacted if the patient has a hematologic malignancy or an allogeneic bone marrow transplant.

CLASSIFICATION DISCLAIMER

THE CLASSIFICATION AND INTERPRETATION OF ALL VARIANTS IDENTIFIED IN THIS ASSAY REFLECTS THE CURRENT STATE OF MYRIAD'S SCIENTIFIC UNDERSTANDING AT THE TIME THIS REPORT WAS ISSUED. VARIANT CLASSIFICATION AND INTERPRETATION MAY CHANGE FOR A VARIETY OF REASONS, INCLUDING BUT NOT LIMITED TO, IMPROVEMENTS TO CLASSIFICATION TECHNIQUES, AVAILABILITY OF ADDITIONAL SCIENTIFIC INFORMATION, AND OBSERVATION OF A VARIANT IN MORE PATIENTS.

Please contact Myriad Medical Services at 1-800-469-7423 X 3850 to discuss any questions regarding this result.

These test results should only be used in conjunction with the patient's clinical history and any previous analysis of appropriate family members. The patient's clinical history and test results should not be disclosed to a third party, unless related to treatment or payment for treatment, without the patient's express written authorization. It is strongly recommended that these results be communicated to the patient in a setting that includes appropriate genetic consultation. This test was developed and its performance characteristics determined by Myriad Genetic Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that clearance or approval for laboratory-developed tests is not required.

Genetic testing was completed by CLIA and CAP accredited laboratories in the United States located at: 320 Wakara Way, Salt Lake City, UT 84108 and 322 N 2200 W, Salt Lake City, UT 84116 CLIA IDs: 46D0880690, 46D2275645
The following personnel codes and laboratory director signature may reflect remote review of digital data: 28492, 29041

Myriad genetics

56453366

PATIENT COPY CONFIDENTIAL

Integrated BRACAnalysis® with MyRisk™ Hereditary Cancer Test

Clinical & Cancer Family History Information

MyRisk™ Hereditary Cancer Test

RECEIVING HEALTHCARE PROVIDER

Amy Kowalski, CNS
Inspire Family Health
711 W 38TH ST STE F3
AUSTIN, TX 78705

SPECIMEN

Specimen Type: Blood
Draw Date: May 08, 2025
Accession Date: May 10, 2025
Report Date: May 22, 2025

PATIENT

Legal Name: Ladnier, William
Date of Birth: Oct 24, 1990
Patient ID:
Sex at Birth: M
Accession #: 05401802-BLD
Requisition #: 11892680

PERSONAL / FAMILY CANCER HISTORY SUMMARY

FAMILY MEMBER	CANCER / CLINICAL DIAGNOSIS	AGE AT DIAGNOSIS
Patient	None	
Grandfather Maternal	Prostate	64
Uncle Maternal	Prostate	66
Great Grandfather Maternal	Prostate	72

The clinical information displayed here was provided by a qualified healthcare provider on the Test Request Form and other documents, and was not verified by Myriad. Female relatives refers to sex assigned at birth, which is a label given to an individual at birth, typically "male" or "female". Family members listed as "other" are not included in a Tyrer-Cuzick breast cancer risk estimate or other personal/family history assessments. For more information see the Specifications for Personal/Family History Analysis at http://myriad.com/technical-specifications.

The accuracy and completeness of the information provided in the Clinical and Cancer Family History Information section of the report (e.g. height and weight, age of menarche) may significantly affect the accuracy of breast cancer risk estimates provided based on either Tyrer-Cuzick or RiskScore. The impact of breast surgeries and hormone therapy (except hormone replacement therapy) have not been assessed or validated for Tyrer-Cuzick and RiskScore.

RiskScore is not valid, and may significantly over- or under-estimate breast cancer risk for individuals who do not meet the eligibility criteria in effect when the testing was performed. The current criteria are: 1) sex assigned at birth is female 2) age is 18 to 84 years, 3) no personal history of breast cancer, LCIS, hyperplasia (with or without atypia), or a breast biopsy with unknown results, 4) there is no mutation detected in a breast cancer risk gene (other than a monoallelic *CHEK2* mutation in a White/Non-Hispanic or Ashkenazi Jewish individual), 5) the individual's relatives have not been found to have a mutation in a high-penetrance breast cancer risk gene (*BRCA1*, *BRCA2*, *CDH1*, *PALB2*, *PTEN*, *STK11*, *TP53*, a biallelic mutation in *CHEK2*, or the specific mutation c.7271T>G (p.Val2424Gly) in *ATM*) and 6) the sample was submitted with a current Test Request Form and the ordering healthcare provider has not determined that RiskScore is inappropriate for the patient. If this is an amended report for a patient tested in the past, please refer to the MyRisk Technical Specifications at http://myriad.com/technical-specifications for the eligibility criteria in effect at the time of the original testing.

Myriad genetics

56453366

PATIENT COPY CONFIDENTIAL

Integrated BRACAnalysis® with MyRisk™ Hereditary Cancer Test

MyRisk Management Tool

MyRisk™ Hereditary Cancer Test

RECEIVING HEALTHCARE PROVIDER

Amy Kowalski, CNS
Inspire Family Health
711 W 38TH ST STE F3
AUSTIN, TX 78705

SPECIMEN

Specimen Type: Blood
Draw Date: May 08, 2025
Accession Date: May 10, 2025
Report Date: May 22, 2025

PATIENT

Legal Name: Ladnier, William
Date of Birth: Oct 24, 1990
Patient ID:
Sex at Birth: M
Accession #: 05401802-BLD
Requisition #: 11892680

GENETIC RESULT: NEGATIVE - NO CLINICALLY SIGNIFICANT MUTATION IDENTIFIED

At this time, any genetic changes identified in this report are not known to warrant modification of the patient's medical management beyond what is indicated by the patient's personal and family history.

CLINICAL HISTORY ANALYSIS: NO ADDITIONAL MANAGEMENT GUIDELINES IDENTIFIED BASED ON THE CLINICAL HISTORY PROVIDED

Other clinical factors may influence individualized management. This analysis may be incomplete if details about cancer diagnoses, ages, family relationships or other factors were omitted or ambiguous. If this patient also has a clinically significant mutation, the recommendations based on the clinical history analysis should be considered in light of the possibility that this mutation explains all or some of the cancer history in the family.

No clinically significant mutations were identified in this patient. However, based on personal/family history, the patient's cancer risks may still be increased over the general population. See information below.

Please see the Genetic Test Result for more details on any variant(s) detected in this patient, including variant classification information.

The terms "male", "female", "he", "she", "women", and "men" refer to sex assigned at birth.

ADDITIONAL FINDINGS: NO VARIANT(S) OF UNCERTAIN SIGNIFICANCE (VUS) IDENTIFIED

Notes for Personalized Management:

INFORMATION ON HOW CANCER RISKS AND MANAGEMENT ARE DETERMINED

The MyRisk Management Tool provides cancer risk levels based on analysis of genetic test results (see MyRisk Genetic Result) and a summary of medical society management recommendations based on both the genetic test results and a limited analysis of the patient's clinical history related to the risk for breast, colorectal, prostate, melanoma and pancreatic cancers. Here are some important points to understand as you interpret this test report and decide on the best plan for management:

- Comprehensive patient management. The management recommendations presented in this report are a summary of management options recommended by the National Comprehensive Cancer Network (NCCN) and other established medical societies and are general in nature. The patient's actual management should be modified based on personal medical history, surgeries and other treatments. A comprehensive risk assessment and management plan may take into account this report and other aspects of the patient's personal/family medical history (e.g., all known clinical diagnoses), as well as lifestyle, environmental and other factors.

Myriad genetics

MyRisk Management Tool

Name: **Ladnier, William** DOB: **Oct 24, 1990** Accession #: **05401802-BLD** Report Date: **May 22, 2025**

- Risk estimates based on provider-supplied information. Some of the risk estimates and management recommendation summaries provided in this report are based on our interpretation of information supplied by the ordering health care provider on the test request form (see Specifications for Personal/Family History analysis at myriad.com/technical-specifications). The patient's actual risks and appropriate management may be significantly different if details provided for cancer diagnoses, ages, family relationships or other factors were incorrect, omitted, ambiguous or have since changed. Please review the clinical history listed on the Clinical & Family History Information page of this report to make sure that the information used was provided and interpreted correctly.
- Variability in Tyrer-Cuzick risk estimates. Tyrer-Cuzick estimates of breast cancer risk can vary significantly based on the way in which the model is used, and the estimate provided here may be higher or lower than what would be calculated by other users. For complete details of how Myriad calculates Tyrer-Cuzick risk estimates, including how Myriad handles information provided in a format not compatible with the model, please see the Specifications for Personal/Family History analysis at myriad.com/technical-specifications. These Specifications also include information for recalculating the Tyrer-Cuzick breast cancer risk estimate if desired.
- What is meant by "High Risk" and "Elevated Risk"? In the Genetic Test Result Summary, a gene-associated cancer risk is described as "High Risk" for a cancer type if all of the following conditions are met: the absolute risk of cancer is approximately 5% or higher, the increase in risk over the general population is approximately 2 to 3-fold or higher, and there is significant data from multiple studies supporting the cancer risk estimate. A gene is described as "Elevated Risk" for a cancer type if there is sufficient data to support an increase in cancer risk over the general population risk, but not all criteria for "High Risk" are met.

INFORMATION FOR FAMILY MEMBERS

Family members should talk to their healthcare providers about hereditary cancer testing to help define their own risk and assist in the interpretation of this patient's genetic test result.

Please contact Myriad Medical Services at 1-800-469-7423 X 3850 to discuss any questions regarding this result.

END OF MANAGEMENT TOOL

myriad®

You have access to a consult with a patient educator, **a board-certified genetic counselor at no additional cost.**

What is a consult?

A phone-based consult with a patient educator, a board-certified genetic counselor is included with your myRisk® Hereditary Cancer Test results. A consult can help you better understand your results and answer any questions that you may have.

What is a patient educator?

Patient educators are board-certified genetic counselors, who are specially trained and certified by the American Board of Genetic Counseling and can provide the information and support you may need to better understand the results of your genetic test. At Myriad, your test includes a consult with a Myriad patient educator.

How do I sign up for a consult?

1. Visit my.myriad.com/consults where you can register for an account.
2. You will be directed to schedule your consult with a patient educator, a board-certified genetic counselor.

Please note you will need to know the Accession # from your report in order to sign up for a session. Write it down for your reference below:

— — — — — — — — **-BLD**

3. After signing up for a consult, you will receive an email confirmation.
4. If you need to make any changes to your consult session, you can do so via your account or your email address.

Need help booking a consult?

If you don't have access to the internet or need help setting up a consult, call 800-469-7423, press 9 and enter extension 3850. Ask for assistance with scheduling a consult with the Patient Education team to discuss your results.

Steps to Schedule

Your Genetic Counseling Consult:

1. Visit **my.myriad.com/consults**
2. Select **Patients**
3. Select **Schedule a Genetic Consult**
4. Enter **First & Last Name**
5. Enter **Email Address**
6. Create a **password** (8 or more characters with at least 1 capital letter)
7. **Agree** to privacy terms & Submit
8. Under **My Consults** select "Schedule a Consult"
9. Confirm your **contact information**
10. **Select your consult** will be for myRisk Hereditary Cancer Test
11. **Confirm** Appointment Details
12. **Select Day & Time** to have a patient educator, a board certified genetic counselor, contact your for appointment

An email confirming the appointment will be generated & sent to the email address provided

myriad®

05401802-BLD

myriad®

Tiene acceso a una consulta gratis con una educadora de pacientes, **cual es una consejera genética certificada.**

¿Qué es una consulta?

Los resultados de la prueba para cáncer hereditario myRisk, incluye una consulta telefónica con una educadora de pacientes, cual es una consejera genética certificada. Una consults puede ayudar que usted entienda mejor sus resultado, o cualquier pregunta que pueda tener.

¿Qué es una educadora de pacientes?

Una educadora de pacientes fue especialments entrenada y certificada por la Junta Americana de Consejeras Genéticas y pueden dar apoyo y la información que necesite para entender mejor los resultados de su prueba genética. Su prueba con Myriad, incluye una consulta con una educadora de pacientes.

¿Cómo me registro para una consulta?

1. Visite my.myriad.com/consults donde puede registrarse para obtener una cuenta.
2. Se le incicara como coordinar su cita con una educadora de pacientes, cual es una consejera genética certificada.

Para registrarse para su cita necesitara su "Accession #" este número se encuentra en su reporte. Apuntelo aquí:

— — — — — — — — **-BLD**

3. Después de registrarse para una cita, recibirá una confirmación por correo electrónico.
4. Si necesita cambiar algo sobre su cita, lo podrá hacer a través de su cuenta o por correo electrónico.

¿Necesitas ayuda para programar una consulta?

Si no tienes acceso al internet o necesitas ayuda para programar una consulta, llame al número 800-469-7423, o prima 9 e ingrese el número de extensión 3850. Solicite ayuda para programar una consulta con el equipo de Educación al Paciente para discutir sus resultados.

Pasos para coordinar su cita
Su cita de asesoramiento genética

1. Visite www.my.myriad.com/consults; La página web esta escrita en Ingles, los siguientes pasos se refieren a los títulos que encontrara y una descripción de lo que está completando en ese paso:
2. Seleccion “Patients” para entrar en la sección de pacientes
3. Seleccione “Schedule a Genetic Consult” para coordinar su cita
4. Escriba su Nombre y Apellido en la sección “First & Last Name”
5. Escriba su correo electrónico en “Email address”
6. Escriba una contra seña seleccione en la sección “password”. (Su contra seña debería contener 8 caracteres o más y tener por lo menos una letra mayúscula)
7. Acepte los términos de privacidad al seleccionar “By checking this box, I confirm that I have read, understand and agree to Myriad Women’s Health’s Terms of Service and Privacy Policy.*”
8. En la sección “My Consults” seleccione “Schedule a Consult” para coordinar su cita
9. Confirme su información personal (nombre, apellido, fecha de nacimiento, numero de teléfono, correo electrónico, y el estado en que vive)
10. Para seleccionar el tipo de consulta necesitara seleccionar “counseling for myRisk Hereditary Cancer Test” Y escribir el “Accession #” cual anoto arriba. Ese número también se encuentra en sus resultados debajo de su nombre y termina con las letras BLD. En esta sección puede incluir un mensaje para su consejera genética. Por ejemplo, podría dejarle saber a la consejera que solo habla español.
11. Confirme los detalles de su información y tipo de visita. Seleccione “continue” para continuar
12. Una página abrirá. Seleccione la hora y el día que desea la que la consejera genética certificada le contacte para su cita.

Recibirá una confirmación de su cita a través del correo electrónico que dio

myriad®

05401802-BLD

Negative

Understanding your MyRisk® report

Your MyRisk® report has three sections

ⓘ Images are for reference only, they do not reflect your results.

1. Genetic result

Your result is negative.

This section of the report describes your results. A negative result means no genetic changes linked to an increased chance of developing cancer were found in the genes tested. This **does not** mean that you have zero cancer risk. Factors such as family history, diet, lifestyle, environment and genes not tested may influence risk, and should be discussed with your healthcare provider.

View results on the first page of your report.

2. Family health history



PERSONAL / FAMILY CANCER HISTORY SUMMARY

FAMILY MEMBER	CANCER / CLINICAL DIAGNOSIS	AGE AT DIAGNOSIS
Patient	Colorectal Polyps: 1	Not Provided
Father	Colorectal Polyps: 100-999	52
Uncle Paternal	Melanoma	45[≈]
Brother	Colorectal Polyps: # Not Specified	36

PATIENT CLINICAL HISTORY SUMMARY

Patient's age	39	Hormone Replacement Therapy (HRT)	Not Specified
Ancestry	White/Non-Hispanic	- HRT: Treatment Type	Not Specified
Height	5 ft 7 in	- HRT: Current user	Not Specified
Weight	175 lbs	- Number of years ago started	Not Specified
Age of menarche	13	- Additional years of intended use	Not Specified
Patient's menopausal status	Pre-menopausal	- HRT: Past user	Not Specified
- Age of onset	N/A	- Number of years ago ended	Not Specified
Age of first live birth	27	Breast biopsy	No Benign Disease

This section contains personal and family health history that your healthcare provider provided to the lab when ordering your test.

3. MyRisk Management Tool



The MyRisk Management Tool includes a results summary. Because your result is negative, there are no recommended adjustments to your medical care. However, it's important to consult with your healthcare provider to create a personalized care plan.

Myriad genetics®

MyRisk®
Hereditary Cancer Test

PRD-1025.05 MGMRHCNEGPET / 02-25

myriad.com/myrisk

05401802-BLD

Terms you might see in your report

Variant of uncertain clinical significance (VUS)

A VUS is a type of genetic change with unknown health impacts. Medical care decisions should **not** be made based on a VUS. If new information about a VUS found in your test becomes available that could affect your medical care or provide information about your cancer risks, Myriad will contact your healthcare provider.

Breast cancer RiskScore®

RiskScore estimates the chance that a person might develop breast cancer. The score is calculated using personal and family health history and genetic information from this test. The RiskScore bar chart compares your lifetime breast cancer risk (pink) with that of the general population (gray). People with a score of 20% or higher may need additional breast cancer screening.



Tyrer-Cuzick risk calculation

Tyrer-Cuzick is also a tool that estimates the chance that a person might develop breast cancer in their lifetime. The calculation only uses personal and family health history. People with a risk calculation of 20% or higher may need additional breast cancer screening.

Single site MyRisk analysis

Single site tests look for a specific genetic change in one gene. If a member of your family has tested positive for a genetic change linked to an increased chance of developing cancer, your healthcare provider might have ordered testing for that specific genetic change.

Next steps

- **Discuss** results with your healthcare provider.
- **Share** results with family members and encourage them to talk to their healthcare provider about hereditary cancer testing.
- **Consult** a genetic counselor via the National Society of Genetic Counselors: findageneticcounselor.nsgc.org
- **Update** your healthcare provider about any changes to your personal or family health history. These updates might impact your care plan.
- **Review** our resources

  Educational session with a board-certified genetic counselor patient.myriad.com
  Information about the genes tested with MyRisk myriad.com/gene-table
  Financial assistance and billing myriad.com/affordability

Myriad genetics®

MyRisk®
Hereditary Cancer Test

PRD-1025.05 MGMRHCNEGPET / 02-25

myriad.com/myrisk

05401802-BLD